GPH101
Phase 1- Indications
- Sickle cell disease
Company intelligence / Profile preview
Alliqua BioMedical
Langhorne, Pennsylvania, United Statesalliqua.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company developed Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is designed to inhibit the function of transcription factor EGR1 in the dorsal root ganglia and spinal cord when administered at the time of surgery.
- Therapeutic areas
- DermatologyImmunologyNeurology
- Modalities
- HydrogelsTransdermal drug delivery systems
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Alliqua BioMedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alliqua BioMedical.